

Title (en)  
IMPROVED TREATMENT OF MULTIPLE MYELOMA

Title (de)  
VERBESSERTE BEHANDLUNG DES MULTIPLLEN MYELOMS

Title (fr)  
L'AMÉLIORATION DU TRAITEMENT DU MYÉLOME MULTIPLE

Publication  
**EP 2029155 B1 20160413 (EN)**

Application  
**EP 07757603 A 20070228**

Priority  
• US 2007062936 W 20070228  
• US 81360606 P 20060228

Abstract (en)  
[origin: WO2007101235A2] The present invention relates to combinations of aplidine or aplidine analogues with other antitumoral agents, and the use of these combinations in the treatment of cancer, in particular in the treatment of lung cancer, breast cancer, colon cancer, prostate cancer, renal cancer, melanoma, multiple myeloma, leukemia and lymphoma.

IPC 8 full level  
**A61K 38/15** (2006.01); **A61K 31/00** (2006.01); **A61K 38/00** (2006.01); **A61K 38/20** (2006.01); **A61K 38/21** (2006.01); **A61K 45/06** (2006.01); **A61K 45/08** (2006.01)

CPC (source: EP KR NO US)  
**A61K 31/00** (2013.01 - KR); **A61K 38/00** (2013.01 - KR); **A61K 38/15** (2013.01 - EP NO US); **A61K 38/2013** (2013.01 - EP NO US); **A61K 38/212** (2013.01 - EP NO US); **A61K 45/06** (2013.01 - EP NO US); **A61P 7/00** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 13/08** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **A61K 2300/00** (2013.01 - NO)

Citation (examination)  
• WO 03033013 A1 20030424 - PHARMA MAR SA [ES], et al  
• LOLA CASALS: "PharmaMar Reports Positive Phase II Results on Aplidin(R) in Patients With Advanced Multiple Myeloma at ASH", PR NEWSWIRE, 12 December 2005 (2005-12-12), UK, pages 1 - 2, XP055099566

Cited by  
US10538535B2; US11332480B2; US11339180B2; US11713325B2

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)  
AL BA HR MK RS

DOCDB simple family (publication)  
**WO 2007101235 A2 20070907; WO 2007101235 A3 20080403**; AU 2007220050 A1 20070907; AU 2007220050 B2 20130829; CA 2643238 A1 20070907; CA 2643238 C 20160503; CN 101389347 A 20090318; CN 101389347 B 20130327; CY 1117722 T1 20170517; DK 2029155 T3 20160801; EP 2029155 A2 20090304; EP 2029155 A4 20091014; EP 2029155 B1 20160413; ES 2575518 T3 20160629; HK 1127294 A1 20090925; HR P20160646 T1 20160812; HU E028055 T2 20161128; IL 193094 A0 20110801; IL 193094 A 20150630; JP 2009528379 A 20090806; JP 2013199500 A 20131003; JP 5393159 B2 20140122; KR 101512503 B1 20150415; KR 20080105123 A 20081203; KR 20140101014 A 20140818; ME 02450 B 20160920; MX 2008010999 A 20080908; NO 20084047 L 20081125; NO 342012 B1 20180312; NZ 571043 A 20120629; PL 2029155 T3 20160930; PT 2029155 E 20160617; RS 54928 B1 20161031; RU 2008138560 A 20100410; RU 2481853 C2 20130520; SI 2029155 T1 20160630; US 2009246168 A1 20091001; US 8258098 B2 20120904

DOCDB simple family (application)  
**US 2007062936 W 20070228**; AU 2007220050 A 20070228; CA 2643238 A 20070228; CN 200780006866 A 20070228; CY 161100620 T 20160705; DK 07757603 T 20070228; EP 07757603 A 20070228; ES 07757603 T 20070228; HK 09106467 A 20090716; HR P20160646 T 20160610; HU E07757603 A 20070228; IL 19309408 A 20080728; JP 2008557477 A 20070228; JP 2013144436 A 20130710; KR 20087023662 A 20070228; KR 20147021341 A 20070228; ME P11516 A 20070228; MX 2008010999 A 20070228; NO 20084047 A 20080923; NZ 57104307 A 20070228; PL 07757603 T 20070228; PT 07757603 T 20070228; RS P20160545 A 20070228; RU 2008138560 A 20070228; SI 200731777 A 20070228; US 27855907 A 20070228